Affiliation: University of Heidelberg
Rath M, Uhlmann L, Heil J, Domschke C, Roth Z, Sinn H, et al
. Predictors of Residual Tumor in Breast-Conserving Therapy. Ann Surg Oncol. 2015;22 Suppl 3:S451-8 pubmed publisher
Mayer C, Brucker J, Schuetz F, Domschke C, Bechstein S, Heil J, et al
. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. Arch Gynecol Obstet. 2016;294:123-9 pubmed publisher
..Further observations are needed to confirm these preliminary experiences on a larger number of patients. ..
Brecht L, Wallwiener M, Schott S, Domschke C, Dinkic C, Golatta M, et al
. Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. Surg Endosc. 2018;32:1002-1011 pubmed publisher
..7 °C (range 63.1-94.2 °C) after bipolar sealing. The median SCD score was 10.47 (range 7.16-13.72). All the instruments used seemed safe for use on the patient. The SCD score allows an indirect comparability of the instruments. ..
Rom J, von Minckwitz G, Marme F, Ataseven B, Kozian D, Sievert M, et al
. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. Ann Oncol. 2009;20:1829-35 pubmed publisher
..Nevertheless, we demonstrated feasibility to process clinical samples and to obtain good quality RNA from tumor biopsies and indicated the potential of oblimersen to lower Bcl-2 mRNA in breast cancer. ..
Rath M, Uhlmann L, Fiedler M, Heil J, Golatta M, Dinkic C, et al
. Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up-a case-control study. Arch Gynecol Obstet. 2018;297:443-447 pubmed publisher
..7 months, cancer recurrence was observed in two patients. Oncotype DX® testing can be recommended for risk-tailored chemotherapy. Results should be validated in larger prospective studies. ..